<DOC>
	<DOCNO>NCT02365649</DOCNO>
	<brief_summary>To determine efficacy safety multiple dose ABT-494 subject moderately severely active Crohn 's Disease history inadequate response intolerance Immunomodulators anti-Tumor Necrosis Factor ( TNF ) therapy .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-Blind , Placebo-Controlled Study ABT-494 Induction Symptomatic Endoscopic Remission Subjects With Moderately Severely Active Crohn 's Disease Who Have Inadequately Responded Are Intolerant Immunomodulators Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>1 . Diagnosis Crohn 's disease ( CD ) least 90 day . 2 . Crohn 's Disease Activity Index ( CDAI ) great equal 220 less equal 450 . 3 . Subject inadequately respond experience intolerance previous treatment immunomodulators ( e.g . azathioprine , 6mercaptopurine , methotrexate ) and/or antiTNF agent ( e.g. , infliximab , adalimumab , certolizumab pegol ) . 1 . Subjects ulcerative colitis ( UC ) , collagenous colitis indeterminate colitis . 2 . Subject surgical bowel resection past 6 month plan resection . 3 . Subjects ostomy ileoanal pouch . 4 . Subject symptomatic bowel stricture abdominal perianal abcess . 5 . Subject short bowel syndrome . 6 . Subject recur infection active Tuberculosis ( TB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>